1,033
Views
0
CrossRef citations to date
0
Altmetric
Report

Electrostatic properties of human germlines and biodistribution of small biologics

, , , , &
Article: 2311991 | Received 25 Oct 2023, Accepted 25 Jan 2024, Published online: 09 Feb 2024

References

  • Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacomet Syst Pharmacol. 2017;6(9):576–9. doi:10.1002/psp4.12224.
  • Hamano Y, Grunkemeyer JA, Sudhakar A, Zeisberg M, Cosgrove D, Morello R, Lee B, Sugimoto H, Kalluri R. Determinants of vascular permeability in the kidney glomerulus. J Biol Chem. 2002;277(34):31154–62. doi:10.1074/jbc.M204806200.
  • Carter LM, Poty S, Sharma SK, Lewis JS. Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy—Model, vector, and radionuclide selection. J Label Compd Radiopharm. 2018;61(9):611–35. doi:10.1002/jlcr.3612.
  • Deonarain MP. Miniaturised ‘antibody’-drug conjugates for solid tumours? Drug Discov Today Technol. 2018;30:47–53. doi:10.1016/j.ddtec.2018.09.006.
  • Deonarain MP, Yahioglu G, Stamati I, Pomowski A, Clarke J, Edwards BM, Diez-Posada S, Stewart AC. Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours? Antibodies. 2018;7(2):16. doi:10.3390/antib7020016.
  • Datta-Mannan A, Lu J, Witcher DR, Leung D, Tang Y, Wroblewski VJ. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies. MAbs. 2015;7(6):1084–93. doi:10.1080/19420862.2015.1075109.
  • Huotari J, Helenius A. Endosome maturation. EMBO J. 2011;30(17):3481–500. doi:10.1038/emboj.2011.286.
  • Pyzik M, Sand KMK, Hubbard JJ, Andersen JT, Sandlie I, Blumberg RS. The neonatal fc receptor (FcRn): a misnomer? Front Immunol. 2019;10:1540. doi:10.3389/fimmu.2019.01540.
  • Miner JH. The Glomerular Basement Membrane. Exp Cell Res. 2012;318(9):973–78. doi:10.1016/j.yexcr.2012.02.031.
  • Christensen EI, Birn H, Storm T, Weyer K, Nielsen R. Endocytic receptors in the renal proximal tubule. Physiol Bethesda Md. 2012;27(4):223–36. doi:10.1152/physiol.00022.2012.
  • Terpstra V, van Amersfoort ES, van Velzen AG, Kuiper J, van Berkel TJC. Hepatic and extrahepatic scavenger receptors. Arterioscler Thromb Vasc Biol. 2000;20(8):1860–72. doi:10.1161/01.ATV.20.8.1860.
  • Boswell CA, Tesar DB, Mukhyala K, Theil F-P, Fielder PJ, Khawli LA. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem. 2010;21(12):2153–63. doi:10.1021/bc100261d.
  • Hu S, Shively L, Raubitschek A, Sherman M, Williams LE, Wong JY, Shively JE, AM W. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 1996;56:3055–61.
  • De S, Kuwahara S, Saito A. The endocytic receptor megalin and its associated proteins in proximal tubule epithelial cells. Membranes. 2014;4(3):333–55. doi:10.3390/membranes4030333.
  • Vash B, Phung N, Zein S, DeCamp D. Three complement-type repeats of the low-density lipoprotein receptor-related protein define a common binding site for RAP, PAI-1, and lactoferrin. Blood. 1998;92(9):3277–85. doi:10.1182/blood.V92.9.3277.
  • Bu G, Rennke S. Receptor-associated protein is a folding chaperone for low density lipoprotein receptor-related protein. J Biol Chem. 1996;271(36):22218–24. doi:10.1074/jbc.271.36.22218.
  • Bryniarski MA, Zhao B, Chaves LD, Mikkelsen JH, Yee BM, Yacoub R, Shen S, Madsen M, Morris ME. Immunoglobulin G is a novel substrate for the endocytic protein megalin. AAPS J. 2021;23(2):40. doi:10.1208/s12248-021-00557-1.
  • Klassen RBS, Allen PL, Batuman V, Crenshaw K, Hammond TG. Light chains are a ligand for megalin. J Appl Physiol Bethesda Md. 2005;98(1):257–63. doi:10.1152/japplphysiol.01090.2003.
  • Schoch A, Kettenberger H, Mundigl O, Winter G, Engert J, Heinrich J, Emrich T. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci U S A. 2015;112(19):5997–6002. doi:10.1073/pnas.1408766112.
  • Kobayashi N, Suzuki Y, Tsuge T, Okumura K, Ra C, Tomino Y. FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells. Am J Physiol Renal Physiol. 2002;282(2):F358–365. doi:10.1152/ajprenal.0164.2001.
  • Akilesh S, Huber TB, Wu H, Wang G, Hartleben B, Kopp JB, Miner JH, Roopenian DC, Unanue ER, Shaw AS. Podocytes use FcRn to clear IgG from the glomerular basement membrane. Proc Natl Acad Sci U S A. 2008;105(3):967–72. doi:10.1073/pnas.0711515105.
  • Goldberg S, Harvey SJ, Cunningham J, Tryggvason K, Miner JH. Glomerular filtration is normal in the absence of both agrin and perlecan–heparan sulfate from the glomerular basement membrane. Nephrol Dial Transplant. 2009;24(7):2044–51. doi:10.1093/ndt/gfn758.
  • Takahashi S, Wada N, Harada K, Nagata M. Cationic charge-preferential IgG reabsorption in the renal proximal tubules. Kidney Int. 2004;66(4):1556–60. doi:10.1111/j.1523-1755.2004.00920.x.
  • Takahashi S. Origin of proteinuria as observed from qualitative and quantitative analysis of serum and urinary proteins. Child Kidney Dis. 2015;19(2):65–70. doi:10.3339/chikd.2015.19.2.65.
  • Daly NL, Scanlon MJ, Djordjevic JT, Kroon PA, Smith R. Three-dimensional structure of a cysteine-rich repeat from the low-density lipoprotein receptor. Proc Natl Acad Sci. 1995;92(14):6334–38. doi:10.1073/pnas.92.14.6334.
  • Bhandari S, Larsen AK, McCourt P, Smedsrød B, Sørensen KK. The scavenger function of liver sinusoidal endothelial cells in health and disease. Front Physiol. 2021;12:757469. doi:10.3389/fphys.2021.757469.
  • Ghitescu L, Fixman A. Surface charge distribution on the endothelial cell of liver sinusoids. J Cell Biol. 1984;99(2):639–47. doi:10.1083/jcb.99.2.639.
  • Glanville J, Zhai W, Berka J, Telman D, Huerta G, Mehta GR, Ni I, Mei L, Sundar PD, Day GMR. et al. Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. Proc Natl Acad Sci. 2009;106(48):20216–21. doi:10.1073/pnas.0909775106.
  • Teplyakov A, Obmolova G, Malia TJ, Luo J, Muzammil S, Sweet R, Almagro JC, Gilliland GL. Structural diversity in a human antibody germline library. MAbs. 2016;8(6):1045–63. doi:10.1080/19420862.2016.1190060.
  • Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, Aso Y. et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel. 2010;23(5):385–92. doi:10.1093/protein/gzq009.
  • Li B, Tesar D, Boswell CA, Cahaya HS, Wong A, Zhang J, Meng YG, Eigenbrot C, Pantua H, Diao J. et al. Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge. MAbs. 2014;6(5):1255–64. doi:10.4161/mabs.29809.
  • Jayaram N, Bhowmick P, Martin ACR. Germline VH/VL pairing in antibodies. Protein Eng Des Sel PEDS. 2012;25(10):523–30. doi:10.1093/protein/gzs043.
  • Ahmed L, Gupta P, Martin KP, Scheer JM, Nixon AE, Kumar S. Intrinsic physicochemical profile of marketed antibody-based biotherapeutics. Proc Natl Acad Sci U S A. 2021;118(37):e2020577118. doi:10.1073/pnas.2020577118.
  • DeKosky BJ, Kojima T, Rodin A, Charab W, Ippolito GC, Ellington AD, Georgiou G. In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire. Nat Med. 2015;21(1):86–91. doi:10.1038/nm.3743.
  • DeKosky BJ, Lungu OI, Park D, Johnson EL, Charab W, Chrysostomou C, Kuroda D, Ellington AD, Ippolito GC, Gray JJ. et al. Large-scale sequence and structural comparisons of human naive and antigen-experienced antibody repertoires. Proc Natl Acad Sci U S A. 2016;113(19):E2636–2645. doi:10.1073/pnas.1525510113.
  • Cunningham O, Scott M, Zhou ZS, Finlay WJJ. Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns. MAbs. 2021;13(1):1999195. doi:10.1080/19420862.2021.1999195.
  • Antibody therapeutics approved or in regulatory review in the EU or US. [Internet]. Antib. Soc. [cited 2022 Jul 11]; Available from: https://www.antibodysociety.org/resources/approved-antibodies/
  • Honegger A, Plückthun A. Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool. J Mol Biol. 2001;309(3):657–70. doi:10.1006/jmbi.2001.4662.
  • Lefranc M-P, Pommié C, Ruiz M, Giudicelli V, Foulquier E, Truong L, Thouvenin-Contet V, Lefranc G. IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev Comp Immunol. 2003;27(1):55–77. doi:10.1016/S0145-305X(02)00039-3.
  • Giudicelli V, Duroux P, Ginestoux C, Folch G, Jabado-Michaloud J, Chaume D, Lefranc M-P. IMGT/LIGM-DB, the IMGT comprehensive database of immunoglobulin and T cell receptor nucleotide sequences. Nucleic Acids Res. 2006;34(90001):D781–784. doi:10.1093/nar/gkj088.
  • Dunbar J, Krawczyk K, Leem J, Marks C, Nowak J, Regep C, Georges G, Kelm S, Popovic B, Deane CM. SAbPred: a structure-based antibody prediction server. Nucleic Acids Res. 2016;44(W1):W474–8. doi:10.1093/nar/gkw361.
  • Jurrus E, Engel D, Star K, Monson K, Brandi J, Felberg LE, Brookes DH, Wilson L, Chen J, Liles K. et al. Improvements to the APBS biomolecular solvation software suite. Protein Sci Publ Protein Soc. 2018;27(1):112–28. doi:10.1002/pro.3280.